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Although cancer cells express antigens recognizable to the immune system, tumors employ a number of diverse
mechanisms aimed at subverting the host anti-tumor immune response. Tumor immune evasion pathways have
been most thoroughly studied in solid tumors. However, emerging data has demonstrated that malignancies of
hematopoietic origin are also able to co-opt their local environment in order to escape immune attack. Activated T
cells upregulate negative costimulatory receptors, such as programmed death-1 (PD-1) and cytotoxic lymphocyte
antigen-4 (CTLA-4). Engagement of PD-1 or CTLA-4 with ligands expressed on tumor cells or professional antigen
presenting cells results in down-regulation of effector T cell function and represents a potent mechanism of immune
evasion across a number of human cancers. Antibodies which block PD-1 / PD-L1 interactions have demonstrated
remarkable activity in a number of solid tumor subtypes. Interestingly, recent data have demonstrated that in select
subtypes of Hodgkin (HL) and non-Hodgkin lymphoma (NHL), the PD-1 ligands are over-expressed due to a genetic
amplification of the loci encoding them. Other mechanisms of PD-L1 over-expression in lymphoma have also been
elucidated. Reports from early-phase clinical trials of PD-1 blockade have demonstrated remarkable effectiveness in HL,
and also appear active against some NHLs. We review the mechanisms of PD-L1 expression in lymphoma and also the
early results of anti-PD-1 therapy in this disease.Background
Although host immune responses can be spontaneously
generated against malignant cells, the tumor environ-
ment employs pathways which effectively restrain the ex-
pansion and function of invading immune cells. Recently,
the disabling of tumor immune evasion mechanisms has
led to major breakthroughs in the cancer immunotherapy
field. In particular, the administration of antibodies which
interrupt interactions between negative regulatory recep-
tors on tumor-specific T cells and their ligands on tumor
cells or antigen-presenting cells (APCs) has resulted in im-
pressive clinical activity in a number of human cancers
[1]. The PD-1 / PD-L1 (programmed death-ligand 1) path-
way has emerged as a highly relevant immune checkpoint
pathway in a number of solid tumor types. For example,
overall response rates to anti-PD-1 therapy are approxi-
mately 30–40 % in melanoma [2], and are quite durable in
a fraction of responding patients. The clinical effectiveness
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patients. Biomarkers capable of identifying patients more
likely to benefit from anti-PD-1 and other checkpoint
blockade therapies are actively being sought. Recently, re-
curring genetic amplifications of the loci encoding the
PD-1 ligands have been discovered in a subtype of classical
Hodgkin lymphoma (HL), and in a genetically related
non-Hodgkin lymphoma (NHL), indicating that PD-L1
and/or PD-L2 over-expression on lymphoma cells may
play a critical role in immune evasion by these cancers [3].
Recent studies of PD-1 blockade in lymphomas have re-
ported impressive response rates and have generated sig-
nificant excitement for the further development of new
and effective immunotherapies for these diseases [4, 5].
Mechanisms of increased PD-L1 expression in lymphoma
Classically, expression of PD-L1 on tumor cells is regu-
lated by IFN-γ production, typically by T cells in the
tumor environment [6]. In several lymphoma subtypes,
including classical nodular sclerosing Hodgkin lymph-
oma (CNSHL) and mediastinal large B cell lymphoma
(MLBCL), a genetic basis for PD-L1 expression in malig-
nant B cells has been uncovered [3]. Here, frequentess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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tected. Key loci at the 9p24.1 amplification peak in-
cluded PD-L1, PD-L2 and Janus kinase 2 (JAK2). The
increased copy number of PD-L1 and PD-L2 in affected
lymphoma cells correlated with increased protein expres-
sion, which was further amplified by dysregulated Jak2 sig-
naling. In a subsequent study of tumor samples from
relapsed/refractory CNSHL patients enrolled onto a clin-
ical trial of PD-1 blockade, all 10 patient samples analyzed
harbored increased copy numbers of PD-L1 and PD-L2,
implicating genetic amplification of the PD-1 ligands in
Hodgkin/Reed-Sternberg (HRS) cells as a common mech-
anism of immune evasion by CNSHL, particularly as the
disease progresses. Interestingly, 9p24.1 amplifications
have not been identified in mixed cellularity Hodgkin
lymphomas (MCHL) [3], which also frequently over-
express PD-L1 [7]. In the case of MCHL and other EBV-
associated lymphomas, PD-L1 expression is driven by acti-
vator protein-1 (AP-1) signaling or possibly through an
EBV LMP-1-induced mechanism [7]. In contrast, PD-
L1 expression on other lymphomas, where analyzed,
appears to occur more sporadically [8, 9]. These elegant
observations provided strong rationale for clinical
translation of checkpoint blockade therapy with anti-
PD-1 antibodies in selected Hodgkin and non-Hodgkin
lymphomas.
Clinical trials of PD-1 blockade in lymphoma
Based on these pre-clinical observations, as well as the ef-
ficacy of anti-PD-1 therapy in solid cancers, two early-
phase clinical trials of anti-PD-1 antibodies have been
conducted in patients with hematological cancers [4, 5]. In
both, HL patients were enrolled on independent expan-
sion cohorts, and the results in these patients have re-
cently been reported. The first study of the anti-PD-1-
blocking antibody, nivolumab, enrolled 23 patients with
relapsed/refractory HL (22 with CNSHL) [4]. Patients
were treated at a dose of 3 mg/kg every 2 weeks until
achievement of a complete response (CR), or until the
point of tumor progression or development of intolerable
side-effects. Approximately 80 % had progressed after ei-
ther autologous stem cell transplantation or following
therapy with brentuximab vedotin. The overall response
rate (ORR) was 87 % with a CR rate of 17 %. Eighty-six
percent of patients were progression-free at 24 weeks. Sev-
eral responding patients went on to receive an allogeneic
stem cell transplant. The therapy was overall well-
tolerated with few grade 3 or 4 toxicities reported. Al-
though longer follow-up is warranted to document dur-
ation of responses, the ORR following PD-1 blockade in
HL exceed those observed in solid cancers. One caveat is
that all but one of the HL patients on this study had
CNSHL, so the effectiveness of PD-1 blockade in other
HL subtypes remains to be proven. The second report,published in abstract form, included 15 HL patients
treated with another PD-1-blocking antibody, pembrolizu-
mab, at a dose of 10 mg/kg every 2 weeks until disease
progression or the development of excessive toxicity [5].
All patients had progressed after brentuximab vedotin,
and two-thirds had previously received an autologous
stem cell transplant. The ORR was 53 %, with a CR rate of
20 %. Here again, pembrolizumab therapy was well toler-
ated, with only 1 grade 3 toxicity reported.
There are also emerging data suggesting that check-
point blockade therapy (CBT) with PD-1-blocking anti-
bodies may be effective in NHL. Investigators at the
M.D. Anderson Cancer Center recently published their
results of a phase II study of a third PD-1-blocking anti-
body, pidilizumab, in combination with the anti-CD20
antibody, rituximab, for patients with relapsed follicular
lymphoma [10]. This combination was well tolerated
and induced an ORR and CR rate of 66 and 52 %, re-
spectively. Although it is impossible to tease out the dir-
ect effect of PD-1 blockade in this study, the ORR to the
combination appeared promising compared to historical
controls treated with rituximab alone. Lastly, the prelim-
inary results of the phase I study of nivolumab in pa-
tients with refractory hematological malignancies were
recently reported [11]. Patients with diffuse large B cell
lymphoma (n = 11) and follicular lymphoma (n = 10)
achieved a 36 and 40 % ORR, respectively. Clearly, PD-1
blockade therapy is active in NHL. However, the follow-
up duration on this study is quite short.
Conclusions
The unique genetic mechanisms underlying PD-L1 over-
expression in CNSHL and PMBL are fascinating and in-
dicate that, in order to subvert an ongoing anti-tumor
immune response, these lymphomas activate PD-1 lig-
and expression [3]. PD-L1 expression also occurs in
other lymphoma subtypes, but less frequently [8, 9].
Early results of CBT with anti-PD-1 antibodies have re-
vealed that they are safe and associated with extremely
high response rates in HL [4, 5]. The FDA has recog-
nized the promise of CBT in HL, and granted nivolumab
Breakthrough Therapy Designation for the treatment of
patients with HL after failure of autologous stem cell
transplant and brentuximab vedotin. Larger studies of
PD-1-blocking antibodies in HL are underway. It is in-
teresting to begin to conceptualize how these agents will
ultimately be incorporated in the treatment of HL pa-
tients, and whether manipulation of other immune
checkpoints in HL will be effective. For this reason, it
will be important to define whether HRS cells commonly
express additional inhibitory ligands that could be targeted
therapeutically. It will also be crucial to identify predictive
biomarkers of response to CBT in HL and NHL. For ex-
ample, does mutational burden in lymphoma correlate
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melanoma and lung cancer [12, 13]? Lastly, the antigens
expressed on lymphoma cells that are recognized by T
cells in the microenvironment are largely unknown. Neo-
antigen discovery through exome and RNA sequencing,
combined with HLA binding prediction and validation,
represents a major next step in improving our understand-
ing the mechanisms which underscore responsiveness to
CBT therapy in lymphoma. Although the numbers of
treated patients are small and follow-up duration limited,
the PD-1 story in HL is one that highlights the importance
of basic scientific discoveries paving the way for transla-
tion of effective cancer therapies into the clinic.
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